nach oben

Current Bladder Dysfunction Reports

Erschienen in:

17.11.2020 | Neurogenic Bladder (C Powell, Section Editor)

Review of Current Neurogenic Bladder Best Practices and International Guidelines

verfasst von: Uttam K. Mete, Charles R. Powell

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Current guidelines for neurogenic bladder (NGB) contain contrasting recommendations in several areas. In this review, the current literature published over the last 5 years will be critically evaluated.

Recent Findings

A number of novel techniques and therapeutic agents have been introduced in the past 5 years or are currently under investigation. Current guidelines do not take these into account. Mirabegron, electromotive onabotulinumtoxin, hydrogel onabotulinumtoxin, progress in neuromodulation (laparoscopic lead implantation, utility in acute and incomplete spinal cord injury (SCI), transrectal neurostimulation, rechargeable MRI-compatible leads and devices), minimally invasive technique and tissue engineering for augmentation cystoplasty (AC), and risk-based surveillance are few of the recent developments in this field.

Summary

NGB is a major global medical and social problem. Many international guidelines are available to assist the clinician to provide best treatment to this patient population. Many of the guidelines, however, have not been updated and do not take into account new developments. Newer drugs and techniques described in the literature over the last 5 years should influence the established guidelines. It may be time to update some existing guidelines.

Blok B, Pannek J, Castro-Diaz D, et al. EAU guidelines on neuro-urology 2019, http://uroweb.org/guideline/neurourology/ (Accessed 16 March 2016).

Madersbacher H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. Paraplegia. 1990;28:217–29.PubMed

•• Powell CR. Not all neurogenic bladders are the same: a proposal for a new neurogenic bladder classification system. Transl Androl Urol 2016;5(1):12–21. This article introduces unique SALE system to efficiently describe a patient suffering from NGB and simultaneously inform the most appropriate treatment, follow-up regimen, and long-term prognosis.

• Liao LM, Zhang F, Chen G. New grading system for upper urinary tract dilation using magnetic resonance urography in patients with neurogenic bladder. BMC Urol. 2014;14: 38–45. LUTD is associated with UUTD. This article describes a new grading system for UUTD including hydronephrosis and ureteral dilatation based on magnetic resonance urography (MRU).

Liao L. Evaluation and management of neurogenic bladder: what is new in China? Int J Mol Sci. 2015;16:18580–600.PubMedPubMedCentral

Chai TC, Kudze T. New therapeutic directions to treat underactive bladder. Investig Clin Urol. 2017;58(Suppl 2):S99–S106. https://doi.org/10.4111/icu.2017.58.S2.S99.CrossRefPubMedPubMedCentral

Patel DP, Myers JB, Lenherr SM. How to measure quality-of-life concerns in patients with neurogenic lower urinary tract dysfunction. Urol Clin North Am. 2017;44(3):345–53.PubMed

Gui-Zhong L, Li-Bo M. Bladder cancer in individuals with spinal cord injuries: a meta-analysis. Spinal Cord. 2017;55:341–5. https://doi.org/10.1038/sc.2016.151.CrossRefPubMed

Cameron AP, Wallner LP, Tate DG, Sarma AV, Rodriguez GM, Clemens JQ. Bladder management after spinal cord injury in the United States 1972 to 2005. J Urol. 2010;184:213–7.PubMed

10.

Zlatev DV, Shem K, Elliott CS. Predictors of long-term bladder management in spinal cord injury patients—upper extremity function may matter most. Neurourol Urodyn. 2018;37:1106–12. https://doi.org/10.1002/nau.23430.CrossRefPubMed

11.

Cameron AP. Medical management of neurogenic bladder with oral therapy. Transl Androl Urol. 2016;5(1):51–62.PubMedPubMedCentral

12.

Madhuvrata P, Singh M, Hasafa Z, et al. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol. 2012;62:816–30.PubMed

13.

• El Helou E, Labaki C, Chebel R, El Helou J, Abi Tayeh G, Jalkh G, Nemr E. The use of mirabegron in neurogenic bladder: a systematic review. World J Urol. 2019. https://doi.org/10.1007/s00345-019-03040-x. Online ahead of print. Mirabegron has been approved for treatment of OAB. Several studies found the utility of this molecule for the treatment of NGB patients. However, due to lack of robust data, it has not yet been approved for NGB. This article highlights this issue.

14.

HidehiroKakizaki KA, Kobayashi S, Tanaka H, Shibata T, Koyanagi T. Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. Int J Urol. 2003;10(11):576–81. https://doi.org/10.1046/j.1442-2042.2003.00710.x.CrossRef

15.

Del Gado R, Aceto G, Del Gaizo D, et al. Desmopressin for the treatment of nocturnal bedwetting in patients with neural tube closure defects. J Urol. 2004;171:1656–8. https://doi.org/10.1097/01.ju.0000117802.33591.f5.CrossRefPubMed

16.

Cameron AP, Clemens JQ, Latini JM, et al. Combination drug therapy improves compliance of the neurogenic bladder. J Urol. 2009;182:1062–7. https://doi.org/10.1016/j.juro.2009.05.038.CrossRefPubMed

17.

Peyronnet B, Brucker BM, Michel MC. Lower urinary tract symptoms: what’s new in medical treatment? Eur Urol Focus. 2018;4(1):17–24. https://doi.org/10.1016/j.euf.2018.04.005.CrossRefPubMed

18.

Joussain C, Phé V, Even A, Chartier-Kastler E, Denys P. Intradetrusor injection of botulinum toxin A and sacral neuromodulation for neurogenic detrusor overactivity. Eur J Phys Rehabil Med. 2017;53(6):991–7. https://doi.org/10.23736/S1973-9087.17.04978-4.CrossRefPubMed

19.

Leitner L, Guggenbühl-Roy S, Knüpfer SC, Walter M, Schneider MP, Tornic J, et al. More than 15 years of experience with intradetrusor onabotulinumtoxinA injections for treating refractory neurogenic detrusor overactivity: lessons to be learned. Eur Urol. 2016;70(3):522–8.PubMed

20.

Leu R, Stearns GL. Complications of Botox and their management. Curr Urol Rep. 2018;19(11):90.PubMed

21.

Jo JK, Kim KN, Kim DW, Kim YT, Kim JY, Kim JY. The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis. World J Urol. 2018;36(2):305–17.PubMed

22.

Ni J, Wang X, Cao N, Si J, Gu B. Is repeat botulinum toxin A injection valuable for neurogenic detrusor overactivity-A systematic review and meta-analysis. Neurourol Urodyn. 2018;37(2):542–53.PubMed

23.

Martínez-Cuenca E, Bonillo MA, Morán E, Broseta E, Arlandis S. Onabotulinumtoxina re-injection for refractory detrusor overactivity using 3-4 injection sites: results of a pilot study. Urology. 2020;137:50–4.PubMed

24.

Zahner PM, Giusto LL, Goldman HB. What is the role of additional pharmacotherapy and neuromodulation in patients with marginal benefit from botulinum toxin injection? Curr Urol Rep. 2018;19(11):91.PubMed

25.

Ferreira RS, D’Ancona CAL, Oelke M, Carneiro MR. IntradetrusoronabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial. Einstein (Sao Paulo). 2018;16(3):eAO4207.

26.

Naqvi S, Clothier J, Wright A, Garriboli M. Urodynamic outcomes in children after single and multiple injections for overactive and low compliance neurogenic bladder treated with abobotulinum toxin A. J Urol. 2020;203(2):413–9.PubMed

27.

Hascoet J, Peyronnet B, Forin V, Baron M, Capon G, Prudhomme T, et al. Intradetrusor injections of botulinum toxin type A in children with spina bifida: a multicenter study. Urology. 2018;116:161–7.PubMed

28.

Gabay B, Maucort-Boulch D, Ruffion A, Scheiber Nogueira MC, Terrier JE. Long-term outcomes of intradetrusor botulinum toxin A in multiple sclerosis patients. Prog Urol. 2019;29(3):156–65.PubMed

29.

Hajebrahimi S, Chapple CR, Pashazadeh F, Salehi-Pourmehr H. Management of neurogenic bladder in patients with Parkinson’s disease: a systematic review. Neurourol Urodyn. 2019;38(1):31–62.PubMed

30.

Peeraully R, Lam C, Mediratta N, Patel R, Williams A, Shenoy M, et al. Intradetrusor injection of botulinum toxin A in children: a 10-year single centreexperience. Int Urol Nephrol. 2019;51(8):1321–7.PubMed

31.

Kaviani A, Khavari R. Disease-specific outcomes of botulinum toxin injections for neurogenic detrusor overactivity. Urol Clin North Am. 2017;44(3):463–74.PubMedPubMedCentral

32.

Myers JB, Lenherr SM, Stoffel JT, Elliott SP, Presson AP, Zhang C, et al. The effects of augmentation cystoplasty and botulinum toxin injection on patient-reported bladder function and quality of life among individuals with spinal cord injury performing clean intermittent catheterization. Neurourol Urodyn. 2019;38(1):285–94. https://doi.org/10.1002/nau.23849.CrossRefPubMed

33.

Anquetil C, Abdelhamid S, Gelis A, Fattal C. Botulinum toxin therapy for neurogenic detrusor hyperactivity versus augmentation enterocystoplasty: impact on the quality of life of patients with SCI. Spinal Cord. 2016;54(11):1031–5. https://doi.org/10.1038/sc.2016.49.CrossRefPubMed

34.

Jhang JF, KuoHC.Novel applications of onabotulinumtoxinA in lower urinary tract dysfunction.Toxins (Basel). 2018;10(7):260.

35.

• Sharifi-Rad L, Ladi-Seyedian SS, Nabavizadeh B, Alijani M, Kajbafzadeh AM. Intravesical electromotive botulinum toxin type A (Dysport) administration in children with myelomeningocele. Urology. 2019;132:210–211. This article describes a newer method of application of intravesical Botox using EMDA technology. This application obviates the need for regional or general anaesthesia. This is desirable for paediatric NGB group requiring multiple follow-up application of intravesical botox.

36.

37.

• Michel F, Ciceron C, Bernuz B, Boissier R, Gaillet S, Even A, et al. Botulinum toxin type A injection after failure of augmentation enterocystoplasty performed for neurogenic detrusor overactivity: preliminary results of a salvage strategy. The ENTEROTOX Study. Urology. 2019;129:43–47. Few patients come back with failure after augmentation cystoplasty. Repeat augmentation is a highly complex surgery and associated with complications. This articles tells us about the utility of intraaugment Botox injection which is efficacious and can help us to avoid complicated redo surgery.

38.

Barboglio Romo PG, Gupta P. Peripheral and sacral neuromodulation in the treatment of neurogenic lower urinary tract dysfunction. Urol Clin North Am. 2017;44(3):453–61.PubMed

39.

Al-Azzawi IS, Al-Tamimi MAJ. The first Iraqi experience in sacral neuromodulation for patients with lower urinary tract dysfunction. Arab J Urol. 2018;16(4):391–6.PubMedPubMedCentral

40.

Sanford MT, Suskind AM. Neuromodulation in neurogenic bladder. Transl Androl Urol. 2016;5(1):117–26.PubMedPubMedCentral

41.

• Parittotokkaporn S, Varghese C, O’Grady G, Svirskis D, Subramanian S, O’Carroll SJ. Non-invasive neuromodulation for bowel, bladder and sexual restoration following spinal cord injury: a systematic review. Clin Neurol Neurosurg. 2020;194: 105822. https://doi.org/10.1016/j.clineuro.2020.105822. Neuromodulation for the treatment of NLUTD has been tried but not yet well established. This systematic review of 46 studies is highly informative about the current status of non-invasive neuromodulation like TENS and magnetic and vibratory stimulation for the treatment of NLUTD.

42.

Xiao CG, Du MX, Dai C, et al. An artificial somatic-central nervous system-autonomic reflex pathway for controllable micturition after spinal cord injury: preliminary results in 15 patients. J Urol. 2003;170:1237–41.PubMed

43.

Xiao CG, Du MX, Li B, et al. An artificial somatic-autonomic reflex pathway procedure for bladder control in children with spina bifida. J Urol. 2005;173:2112–6.PubMed

44.

•• Peters KM, Girdler B, Turzewski C, et al. Outcomes of lumbar to sacral nerve rerouting for spina bifida. J Urol. 2010;184:702–7. This article describes the success story of lumbar to sacral nerve re-routing for restoring bladder and bowel function in spina bifida patients.

45.

Peters KM, Feber KM, Bennett RC. A prospective, single-blind,randomized crossover trial of sacral vs pudendal nerve stimulation for interstitial cystitis. BJU Int. 2007;100:835–9.PubMed

46.

Kolodziej M, Uhl E, Schwarm F, Nagl J, Schürg R, Meinhold-Heerlein I, et al. Interdisciplinary laparoscopic implantation of neuromodulation leads to the sacral plexus for therapy of chronic pelvic pain and neurogenic bladder dysfunctions. Neuromodulation. 2020. https://doi.org/10.1111/ner.13157.

47.

Erdogru T, Onur R. Laparoscopic selective pudendal neuromodulation for neurogenic bladder: a review of literature. Cent European J Urol. 2020;73(1):39–41.PubMedPubMedCentral

48.

Shi P, Zhao X, Wang J, et al. Effects of acute sacral neuromodulation on bladder reflex in complete spinal cord injury rats. Neuromodul Technol Neural Interface. 2012;16:583–9.

49.

Kumsar Ş, Keskin U, Akay A, et al. Effects of sacral neuromodulation on isolated urinary bladder function in a rat model of spinal cord injury. Neuromodul Technol Neural Interface. 2014;18:67–75.

50.

• Sievert K-D, Amend B, Gakis G, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol. 2010;67:74–84. This study describes the potential influences on human nerves and pelvic organs through early implantation of bilateral sacral nerve modulators (SNMs) in complete spinal cord injury (SCI) patients during the acute bladder-areflexia phase.

51.

Redshaw JD, Lenherr S, Elliott SP, et al. Protocol for a randomized clinical trial investigating early sacral nerve stimulation as an adjunct to standard neurogenic bladder management following acute spinal cord injury. BMC Urol. 2018;18, 72. https://doi.org/10.1186/s12894-018-0383-y.

52.

• Stampas A, Gustafson K, Korupolu R, Smith C, Zhu L, Li S. Bladder neuromodulation in acute spinal cord injury via transcutaneous tibial nerve stimulation: cystometrogram and autonomic nervous system evidence from a randomized control pilot trial. Front Neurosci. 2019;13:119. Utility of neuromodulation in the acute phase of SCI to improve the future bladder dysfunction is a novel idea. In this pilot study, the authors had employed transcutaneous tibial nerve stimulation (TTNS) in acute SCI patients. The authors had noted that the control group had significantly increased detrusor pressure and counts of detrusor sphincter dyssynergia on CMG, not seen in the TTNS group.

53.

Lee YJ, Yoon CY, Lee MS, Song BD, Lee SW, Jeong SJ. Effect of early sacral neuromodulation on bladder function in a rat model of incomplete spinal cord injury due to focal contusion. Neuromodulation. 2019;22(6):697–702.PubMed

54.

• Knight SL, Edirisinghe N, Leaker B, Susser J, Craggs MD. Conditional neuromodulation of neurogenic detrusor overactivity using transrectal stimulation in patients with spinal cord injury: a proof of principle study. Neurourol Urodyn. 2018 Jan;37(1):385–393. In this unique study, the pudendal nerves lying in Alcock’s canal were stimulated transrectally amongst SCI patients and the authors had noted success. This may turn out to be a future less invasive treatment modality.

55.

Tudor KI, Seth JH, Liechti MD, Ochulor J, Gonzales G, Haslam C, et al. Outcomes following percutaneous tibial nerve stimulation (PTNS) treatment for neurogenic and idiopathic overactive bladder. Clin Auton Res. 2020;30(1):61–7.PubMed

56.

Benson K, McCrery R, Taylor C, Padron O, Blok B, Wachter S, et al. One-year outcomes of the ARTISAN-SNM study with the Axonics System for the treatment of urinary urgency incontinence. Neurourol Urodyn. 2020;39(5):1482–8. https://doi.org/10.1002/nau.24376.CrossRefPubMedPubMedCentral

57.

Roth JD, Cain MP. Neuropathic bladder and augmentation cystoplasty. Urol Clin North Am. 2018;45(4):571–85.PubMed

58.

Shreck E, Gioia K, Lucioni A. Indications for augmentation cystoplasty in the era of onabotulinumtoxinA. Curr Urol Rep. 2016;17(4):27.PubMed

59.

Hayashi Y, Nishimura E, Shimizu S, Miyano G, Okawada M, Nagae I, et al. Sigmoidocolocystoplasty for neurogenic bladder reviewed after 20 years. J Pediatr Surg. 2017;52(12):2070–3.PubMed

60.

Phé V, Boissier R, Blok BFM, Del Popolo G, Musco S, Castro-Diaz D, et al. Continent catheterizable tubes/stomas in adult neuro-urological patients: a systematic review. Neurourol Urodyn. 2017;36(7):1711–22.PubMed

61.

Zhang HC, Yang J, Ye X, Hu HF. Augmentation enterocystoplasty without reimplantation for patients with neurogenic bladder and vesicoureteral reflux. Kaohsiung J Med Sci. 2016;32(6):323–6.PubMed

62.

Shepard CL, Wang G, Hopson BD, Bunt EB, Assimos DG. Urinary tract stone development in patients with myelodysplasia subjected to augmentation cystoplasty. Rev Urol. 2017;19(1):11–5.PubMedPubMedCentral

63.

Telli O, Ozcan C, Hamidi N, Karagoz MA, Hascicek AM, Soygur T, et al. Preoperative risk factors predicting complication rates of augmentation cystoplasty using the modified Clavien classification system in paediatric population. Urology. 2016;97:166–71.PubMed

64.

Biardeau X, Chartier-Kastler E, Rouprêt M, Phé V. Risk of malignancy after augmentation cystoplasty: a systematic review. Neurourol Urodyn. 2016;35(6):675–82.PubMed

65.

Cheng PJ, Myers JB. Augmentation cystoplasty in the patient with neurogenic bladder. World J Urol. 2019;11. https://doi.org/10.1007/s00345-019-02919-z.

66.

Perrouin-Verbe MA, Léon P, Denys P, Mongiat-Artus P, Chartier-Kastler E, Phé V. Long-term functional outcomes of augmentation cystoplasty in adult spina bifida patients: a single-center experience in a multidisciplinary team. Neurourol Urodyn. 2019;38(1):330–7.PubMed

67.

Cheng KC, Kan CF, Chu PS, Man CW, Wong BT, Ho LY, et al. Augmentation cystoplasty: urodynamic and metabolic outcomes at 10-year follow-up. Int J Urol. 2015;22(12):1149–54.PubMed

68.

Krebs J, Bartel P, Pannek J. Functional outcome of supratrigonal cystectomy and augmentation ileocystoplasty in adult patients with refractory neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2016;35(2):260–6.PubMed

69.

Budzyn J, Trinh H, Raffee S, Atiemo H. Bladder augmentation (enterocystoplasty): the current state of a historic operation. Curr Urol Rep. 2019;20(9):50. https://doi.org/10.1007/s11934-019-0919-z.CrossRefPubMed

70.

Rehfuss A, Apfeld JC, Sebastião YV, McLeod DJ, Fuchs M, Dajusta D. Utilization of augmentation cystoplasty for myelomeningocele patients remained stable over the past decade. Urology. 2020. https://doi.org/10.1016/j.urology.2020.04.080.

71.

Langer S, Radtke C, Györi E, Springer A, Metzelder ML. Bladder augmentation in children: current problems and experimental strategies for reconstruction. Wien Med Wochenschr. 2019;169(3–4):61–70.PubMed

72.

Mehmood S, Alhazmi H, Al-Shayie M, Althobity A, Alshammari A, Altaweel WM, et al. Long-term outcomes of augmentation cystoplasty in a paediatric population with refractory bladder dysfunction: a 12-year follow-up experience at single center. Int Neurourol J. 2018;22(4):287–94.PubMedPubMedCentral

73.

• VanderBrink BA, Szymanski KM, Alam Z, Misseri R, DeFoor WR, Kaefer M, et al. Risk of reaugmentation after enterocystoplasty using a reconfigured bowel segment in patients with spina bifida: a bi-institutional cohort study. Urol. 2019;202(3):612–616. This article describes the reduced rate of re-augmentation cystoplasty in the recent series compared to earlier series . Most probable reason being improved surgical technique in recent years.

74.

• Kalkan S, Jaffe WI, Simma-Chiang V, Li ESW, Blaivas JG. Long term results of augmentation cystoplasty and urinary diversion in multiple sclerosis. Can J Urol. 2019;26(3):9774–9780. The augmentation cystoplasty is rarely performed for NGB due to multiple sclerosis. This article makes us believe that it is an underutilized procedure for refractory LUTS in MS patients.

75.

Wiestma AC, Estrada CR Jr, Cho PS, Hollis MV, Yu RN. Robotic-assisted laparoscopic bladder augmentation in the paediatricpatient. J Pediatr Urol. 2016;12(5):313.e1–2.

76.

Alberti C. Whyever bladder tissue engineering clinical applications still remain unusual even though many intriguing technological advances have been reached? G Chir. 2016;37(1):6–12.PubMedPubMedCentral

77.

• Zhang F, Liao L. Long-term follow-up of neurogenic bladder patients after bladder augmentation with small intestinal submucosa. World J Urol. 2019. https://doi.org/10.1007/s00345-019-03008-x. To reduce the long-term complication of augmentation, cystoplasty search is on for better alternative. This article describes the use of alternative tissues like SIS (small intestinal submucosa) scaffold for augmentation.

78.

Adamowicz J, Pokrywczynska M, Van Breda SV, Kloskowski T, Drewa T. Concise review: tissue engineering of urinary bladder; we still have a long way to go? Stem Cells Transl Med. 2017;6(11):2033–43.PubMedPubMedCentral

79.

Carrasco A Jr, Vemulakonda VM. Managing adult urinary incontinence from the congenitally incompetent bladder outlet. Curr Opin Urol. 2016;26(4):351–6.PubMed

80.

Derry F, al-Rubeyi S. Audit of bladder neck resection in spinal cord injured patients. Spinal Cord. 1998;36:345–348. https://www.ncbi.nlm.nih.gov/pubmed/9601115.

81.

Tang F, Cheng Z, Wen X, Guan J. Effect of continuous care intervention on the quality of life in patients with neurogenic bladder dysfunction. J Int Med Res. 2019 May;47(5):2011–7.PubMedPubMedCentral

82.

Yuan-Hong Jiang, Sheng-Fu Chen, and Hann-ChorngKuo. Role of videourodynamic study in precision diagnosis and treatment for lower urinary tract dysfunction. Ci Ji Yi Xue Za Zhi 2019; 32(2): 121–130.

83.

Alex Kavanagh, Hamed Akhavizadegan, Matthias Walter, Lynn Stothers, , Blayne Welk, and Timothy B. Boone. Baseline urodynamic characterization in patients with neurogenic lower surveillance urodynamics for neurogenic lower urinary tract dysfunction: A systematic review. Can Urol Assoc J. 2019; 13(4): 133–141.PubMed

84.

• Adriaansen JJE, Floris WA van Asbeck, Bongers-Janssen HMH, Dorien Spijkerman ALLRISC, Visser-Meily JMA, de Kort LMO, Post MWM. Description of urological surveillance and urologic ultrasonography outcomes in a cohort of individuals with long-term spinal cord injury. Top Spinal Cord InjRehabil. 2017 Winter; 23(1): 78–87. This article describes the utility of surveillance ultrasonography to look for upper tract changes amongst patients with LUTD.

85.

• Sammer U, Walter M, Knüpfer SC, Mehnert U, Bode-Lesniewska B, Kessler TM. Do we need surveillance urethro-cystoscopy in patients with neurogenic lower urinary tract dysfunction? PLoS One. 2015; 10(10): e0140970. Occurrence of bladder malignancy amongst NGB patients has prompted many care givers to include surveillance cystoscopy. This article proves that this traditional belief is not justified and cystoscopy is only to be offered for clinical indications like haematuria not for cancer screening.

86.

NICE CG148 2012, https://www.nice.org.uk/guidance/cg148/evidence/full-guideline-188123437\ (Accessed 16 March 2016).

87.

Drake MJ, Apostolidis A, Cocci A, Emmanuel A, Gajewski JB, Harrison SCW, et al. Neurogenic lower urinary tract dysfunction: clinical management recommendations of the Neurologic Incontinence committee of the fifth International Consultation on Incontinence 2013. Neurourol. Urodynam. 2016 First published: 13 May 2016;35:657–65. https://doi.org/10.1002/nau.23027.CrossRef

88.

Kavanagh A, Baverstock R, Campeau L, Carlson K, Cox A, Hickling D, et al. Canadian urological association guideline: diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction – full text. CanUrol Assoc J. 2019;13(6):E157–76.

89.

Winters JC, Dmochowski RR, Goldman HB, Herndon CDA, Kobashi KC, Kraus SR, et al. Urodynamic studies in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2464–72. https://doi.org/10.1016/j.juro.2012.09.081.CrossRefPubMed

90.

Jaggi A. Francis Fatoye Real world treatment patterns in the neurogenic bladder population: a systematic literature review. Transl Androl Urol. 2017;6(6):1175–83.PubMedPubMedCentral

Titel: Review of Current Neurogenic Bladder Best Practices and International Guidelines
verfasst von: Uttam K. Mete
Charles R. Powell
Publikationsdatum: 17.11.2020
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 4/2020
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-020-00622-z

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Assessing In Vivo Bladder Urothelial Hyper-Permeability: Preclinical and Clinical Implications

Management of Pelvic Floor Disorders in Young Women

Urinary Tract Infection and Pelvic Organ Prolapse—an Association that Needs Further Clarification

Treatment of Overactive Bladder in the Frail Patient